Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066625 · ClinicalTrials.gov registry record · Phase 1
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00066625: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00066625 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00066625, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Phase I trial to study the effect on the body of combining oxaliplatin with bortezomib in treating patients who have metastatic or unresectable cancer. Drugs used in chemotherapy such as oxaliplatin use different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth. Combining oxaliplatin with bortezomib may kill more cancer cells
Interventions
- OTHER laboratory biomarker analysis
- DRUG oxaliplatin
- OTHER pharmacological study
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066625
The ClinicalTrials.gov registry entry for NCT00066625 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00066625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066625 about?
NCT00066625 is a clinical study titled "Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer". Phase I trial to study the effect on the body of combining oxaliplatin with bortezomib in treating patients who have metastatic or unresectable cancer. Drugs used in chemotherapy such as oxaliplatin use different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may sto...
What is the current status of trial NCT00066625?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00066625?
The interventions under investigation include: laboratory biomarker analysis (OTHER), oxaliplatin (DRUG), pharmacological study (OTHER), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00066625?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.